Form 4: Agios Pharmaceuticals Director Reports Significant Equity Grants and RSU Vesting

Agios Pharmaceuticals, Inc. Director Kaye Foster-Cheek reported the vesting of 2,120 restricted stock units into common stock and the grant of 2,816 new restricted stock units and 15,768 stock options.

Summary

• Kaye Foster-Cheek, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported recent equity transactions in a Form 4 filing.
• On June 18, 2025, Ms. Foster-Cheek was granted 2,816 Restricted Stock Units (RSUs) and 15,768 stock options.
• The newly granted RSUs and stock options both vest fully on June 18, 2026. The stock options have an exercise price of $35.5 and an expiration date of June 18, 2035.
• On June 20, 2025, 2,120 Restricted Stock Units, which were originally granted on June 20, 2024, vested and were converted into 2,120 shares of common stock.
• Following these transactions, Ms. Foster-Cheek directly holds 7,468 shares of common stock and indirectly holds 2,200 shares through the Foster Family Revocable Trust.
• She also holds 2,816 unvested Restricted Stock Units and 15,768 unvested stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as it indicates ongoing alignment of a director's interests with the company's long-term performance through significant equity grants. While not a direct cash investment, it reflects standard and expected compensation practices that incentivize growth.

Positives

• The grants of new restricted stock units and stock options align the director's interests with long-term shareholder value.
• The vesting of previously granted RSUs demonstrates the realization of equity compensation for the director.
• Increased insider ownership (or potential ownership through options/RSUs) can signal confidence in the company's future prospects.

Negatives

• The transactions primarily involve equity grants and vesting, not open market purchases, which would indicate direct cash investment by the insider.
• The exercise price of the new stock options ($35.5) provides a benchmark for future stock performance required for these options to be 'in the money'.

Future Outlook

The document indicates future vesting events for the newly granted Restricted Stock Units and stock options, with both set to vest fully on June 18, 2026. This aligns the director's future compensation with the company's performance over the next year.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical industry, where long-term incentives like RSUs and stock options are common to align leadership interests with shareholder value creation.

Related Party Transactions

• The indirect ownership of 2,200 common shares by the Foster Family Revocable Trust is a related party transaction, as it involves a trust associated with the reporting person.

Stakeholder Impact

• Shareholders: The grants of RSUs and stock options align the director's incentives with shareholder interests, potentially leading to better long-term performance. The vesting of previous awards demonstrates the realization of equity compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of 2,816 Restricted Stock Units on June 18, 2026.
• Vesting of 15,768 stock options on June 18, 2026.
• Delivery of vested shares within three business days after such shares become vested.

Key Dates

Recommendation

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Director Stock, Kaye Foster-Cheek, Vesting, Share Ownership